Saphnelo (anifrolumab-fnia) is a prescription drug used to treat systemic lupus erythematosus (SLE). It is given as ... But if you think you’re having a medical emergency, you should call ...

One of the most serious manifestations of systemic lupus erythematosus (SLE) is renal involvement, which can progress to end-stage renal disease (ESRD). To identify factors that increase the risk ...

Just 5% of pediatric providers feel highly confident in evaluating and managing neuropsychiatric SLE in youth.

Belimumab combined with standard therapy demonstrated significant improvements in mucocutaneous symptoms in patients with systemic lupus erythematosus (SLE) compared with placebo with standard ...

Rheumatoid arthritis, arthritis and pleurisy of SLE: initially 3g daily in divided doses; target plasma salicylate level 150–300mcg/mL. Osteoarthritis: up to 3g/day in divided doses ...

in terms of IFN response and effects on pDCs. Oral glucocorticoids (5–20 mg/day) failed to normalize the IFN signature in patients with SLE, or to reduce the levels of IFN-α produced by pDCs in ...

The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.